Argenica Therapeutics Ltd
AGN
Company Profile
Business description
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Contact
117 Broadway
Unit 4
NedlandsWA6009
AUST: +61 893293396
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,821.40 | 43.50 | 0.50% |
| CAC 40 | 7,878.46 | 111.75 | 1.44% |
| DAX 40 | 24,549.56 | 342.65 | 1.42% |
| Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
| FTSE 100 | 8,867.02 | 12.84 | 0.15% |
| HKSE | 23,892.32 | 255.75 | -1.06% |
| NASDAQ | 20,611.34 | 192.87 | 0.94% |
| Nikkei 225 | 39,623.95 | 197.33 | -0.50% |
| NZX 50 Index | 12,780.11 | 11.50 | 0.09% |
| S&P 500 | 6,263.26 | 37.74 | 0.61% |
| S&P/ASX 200 | 8,580.40 | 41.80 | 0.49% |
| SSE Composite Index | 3,493.05 | 4.43 | -0.13% |